We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.32%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.02B
AUM Growth
+$175M
Cap. Flow
-$2.02B
Cap. Flow %
-40.15%
Top 10 Hldgs %
37.55%
Holding
141
New
17
Increased
15
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$70.1M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$58M
3
RVMD icon
Revolution Medicines
RVMD
+$44M
4
LRMR icon
Larimar Therapeutics
LRMR
+$27.8M
5
VERV
Verve Therapeutics
VERV
+$23.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$98.4M
2
AHCO icon
AdaptHealth
AHCO
+$60.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$59M
4
GKOS icon
Glaukos
GKOS
+$53.6M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 53.48%
2 Financials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
51
Krystal Biotech
KRYS
$9.92B
$12.2M 0.24%
+175,000
New +$12.6M
PACB icon
52
Pacific Biosciences
PACB
$419M
$11.7M 0.23%
+2,021,000
New +$11.6M
ADCT icon
53
ADC Therapeutics
ADCT
$150M
$11.5M 0.23%
+2,390,297
New +$17.3M
VCEL icon
54
Vericel Corp
VCEL
$2.31B
$11.3M 0.22%
+484,947
New +$13.2M
TERN
55
DELISTED
Terns Pharmaceuticals
TERN
$11M 0.22%
+1,860,000
New +$6.91M
EUCR
56
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$10M 0.2%
999,999
– –
SRSA
57
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$10M 0.2%
999,999
– –
ALEC icon
58
Alector
ALEC
$168M
$9.98M 0.2%
1,055,192
– –
SNRH
59
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
$9.95M 0.2%
1,000,000
– –
TLSI icon
60
TriSalus Life Sciences
TLSI
$266M
$9.93M 0.2%
999,999
– –
REVH
61
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$9.82M 0.2%
1,000,000
– –
APEN
62
DELISTED
Apollo Endosurgery, Inc.
APEN
$9.64M 0.19%
1,750,000
– –
PHVS icon
63
Pharvaris
PHVS
$2.37B
$8.47M 0.17%
1,104,552
-85,791
-7% -$1.34M
PNT
64
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.73M 0.15%
+1,000,000
New +$8.49M
TMPM
65
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$7.5M 0.15%
750,000
– –
PKBO
66
DELISTED
Peak Bio, Inc. Common Stock
PKBO
$7.24M 0.14%
725,000
– –
PEPG icon
67
PepGen
PEPG
$132M
$6.77M 0.13%
745,293
-208,333
-22% -$2.05M
FHTX icon
68
Foghorn Therapeutics
FHTX
$289M
$6.67M 0.13%
777,525
– –
INZY
69
DELISTED
Inozyme Pharma
INZY
$5.6M 0.11%
2,090,436
-605,936
-22% -$2.19M
CALC icon
70
CalciMedica
CALC
$10.9M
$4.97M 0.1%
377,265
– –
OHPA
71
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
$4.92M 0.1%
500,000
– –
HOWL icon
72
Werewolf Therapeutics
HOWL
$20.3M
$4.32M 0.09%
958,125
– –
QSI icon
73
Quantum-Si Incorporated
QSI
$168M
$3.85M 0.08%
1,400,000
– –
ANNX icon
74
Annexon
ANNX
$854M
$3.61M 0.07%
583,913
– –
ORTX
75
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$3.48M 0.07%
694,942
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2022 Portfolio in Review

As of Q3 2022, Deerfield Management held 141 positions worth $5.02B, up 3.6% from $4.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deerfield Management withdrew a net $2.02B in Q3 2022, closing 12 positions and reducing 22 holdings. Its most notable exit was Glaukos, an estimated $53.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 51% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Biogen worth $88.1M.

  • Deerfield Management's largest Q3 2022 buy was Biogen: 330,000 shares worth $88.1M.
  • Deerfield Management added most to Revolution Medicines in Q3 2022, an estimated $44M increase.
  • Deerfield Management's biggest Q3 2022 reduction was Viatris, cutting an estimated $98.4M.
  • Deerfield Management fully exited Glaukos in Q3 2022, selling an estimated $53.6M.
  • Deerfield Management's ten largest holdings make up 38% of its $5.02B portfolio in Q3 2022.
  • Deerfield Management opened 17 new positions and closed 12 in Q3 2022.
  • Deerfield Management's portfolio value rose 3.6% quarter-over-quarter to $5.02B.

Based on Deerfield Management's 13F filing for Q3 2022, filed 14 Nov 2022.